title: Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
abstract: The preparation and investigation of sustained-release risperidone-encapsulated microspheres using erodible poly(D, L-lactide-co-glycolide) (PLGA) of lower molecular weight were performed and compared to that of commercial Risperdal Consta™ for the treatment of schizophrenia. The research included screening and optimizing of suitable commercial polymers of lower molecular weight PLGA50/50 or the blends of these PLGA polymers to prepare microspheres with zero-order release kinetics properties. Solvent evaporation method was applied here while studies of the risperidone loaded microsphere were carried out on its drug encapsulation capacity, morphology, particle size, as well as in vitro release profiles. Results showed that microspheres prepared using 50504A PLGA or blends of 5050-type PLGAs exerted spherical and smooth morphology, with a higher encapsulation efficiency and nearly zero-order release kinetics. These optimized microspheres showed great potential for a better depot preparation than the marketed Risperdal Consta™, which could further improve the patient compliance.
authors.affiliation: College of Life Science, Jilin University, Changchun, China.
authors.forename: Zheng-Xing
authors.initials: ZX
authors.lastname: Su
authors.forename: Ya-Nan
authors.initials: YN
authors.lastname: Shi
authors.forename: Le-Sheng
authors.initials: LS
authors.lastname: Teng
authors.forename: Xiang
authors.initials: X
authors.lastname: Li
authors.forename: Le-xi
authors.initials: LX
authors.lastname: Wang
authors.forename: Qing-Fan
authors.initials: QF
authors.lastname: Meng
authors.forename: Li-Rong
authors.initials: LR
authors.lastname: Teng
authors.forename: You-Xin
authors.initials: YX
authors.lastname: Li
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002626:Chemistry, Pharmaceutical / Q000379:methods*; D003692:Delayed-Action Preparations / Q000737:chemistry* / Q000493:pharmacokinetics; D019344:Lactic Acid / Q000737:chemistry*; D008863:Microspheres; D008970:Molecular Weight; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D018967:Risperidone / Q000008:administration & dosage* / Q000493:pharmacokinetics; D012559:Schizophrenia / Q000188:drug therapy; D012995:Solubility
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D018967:Risperidone